TriPath's p53 breast test analysers:
This article was originally published in Clinica
TriPath Imaging has received US FDA 510(k) market clearance to use a Ventana-branded version of its interactive histology image analysis system with tissues stained for p53, a tumour suppressor biomarker associated with more aggressive breast cancers. The Ventana Image Analysis System (VIAS) has previously been cleared for use with the Ventana oestrogen receptor, progesterone receptor, Ki-67 and HER-2/neu assays. In 2004, TriPath, of Burlington, North Carolina, gave Tucson, Arizona-based Ventana exclusive rights to sell and distribute worldwide a Ventana-branded version of its imaging system, optimised for both Ventana and TriPath assays. "This is the first time the p53 marker has been cleared by the FDA for use with an image analysis system," said Paul Sohmer, TriPath's chairman, president and CEO.
You may also be interested in...
Novartis has long championed the idea of making Sandoz an autonomous unit within the Swiss originator while stopping short of carving out the business altogether. Rumors continue to swirl around a potential deal, which was discussed during the recent virtual Meet Novartis Management event.
Health technology assessment body says that while iRhythm Technologies’ Zio XT service improves cardiac arrhythmia detection, more data must be collected to address evidence gaps about its benefit.
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.